Climb Bio (CLYM) Common Equity (2020 - 2026)
Climb Bio's (CLYM) quarterly Common Equity came in at $148.1 million in Q1 2026, down 23.42% YoY from $193.4 million in Q1 2025, and down 7.72% on a QoQ basis from $160.5 million in Q4 2025.
Climb Bio (CLYM) Common Equity (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Common Equity data on file, last reported at $148.1 million in Q1 2026.
- Quarterly Common Equity fell 23.42% year-over-year to $148.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148.1 million (down 23.42% YoY) and the FY2025 annual result came in at $160.5 million, down 24.26% from the prior year.
- Common Equity eased to $148.1 million in Q1 2026, from $160.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $222.3 million in Q2 2024 to a low of $106.4 million in Q1 2024.
- A 5-year average of $154.8 million and a median of $148.1 million in 2026 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity jumped 459.27% — and 2023, when it dropped 24.68%.
- Tracing CLYM's Common Equity over 5 years: stood at $128.7 million in 2022, then dropped by 16.41% to $107.6 million in 2023, then surged by 96.92% to $211.9 million in 2024, then decreased by 24.26% to $160.5 million in 2025, then dropped by 7.72% to $148.1 million in 2026.
- The last three Common Equity figures came in at $148.1 million (Q1 2026), $160.5 million (Q4 2025), and $177.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 239.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 239.55 Mn |
| Mar 31, 2026 | 148.09 Mn |
| Dec 31, 2025 | 160.48 Mn |
| Sep 30, 2025 | 177.00 Mn |
| Jun 30, 2025 | 185.76 Mn |
| Mar 31, 2025 | 193.39 Mn |
| Dec 31, 2024 | 211.88 Mn |
| Sep 30, 2024 | 218.78 Mn |
| Jun 30, 2024 | 222.28 Mn |
| Mar 31, 2024 | 106.38 Mn |
| Dec 31, 2023 | 107.60 Mn |
| Sep 30, 2023 | 109.74 Mn |
| Jun 30, 2023 | 112.50 Mn |
| Mar 31, 2023 | 116.86 Mn |
| Dec 31, 2022 | 128.72 Mn |
| Sep 30, 2022 | 134.36 Mn |
| Jun 30, 2022 | 142.24 Mn |
| Mar 31, 2022 | 155.14 Mn |
| Dec 31, 2021 | 167.20 Mn |
| Sep 30, 2021 | 176.66 Mn |